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of anti-obesity medication according to social
factors: a population cross sectional study
Lynsey Patterson1,2*, Frank Kee1,2, Carmel Hughes3 and Dermot O’Reilly1,2Abstract
Background: Obesity is a global public health problem. There are a range of treatments available with varying
short and long term success rates. One option is the use of anti-obesity medication the prescription of which has
increased dramatically in recent years. Despite this, little is known about the individual and GP practice factors that
influence the prescription of anti-obesity medication.
Methods: Multi-level logistic regression analysis was used to investigate factors associated with the prescription of
anti-obesity medication in Northern Ireland using a population primary care prescribing database (~1.5 million
people aged 16+ years) during 2009/10.
Results: While 25.0% of people are obese, only 1.3% (2.1% of females, 0.6% of males) received anti-obesity medication.
The relationship between medication rates and age differed by gender (P < 0.001) with prescriptions higher in younger
females and older males. Prescribing of anti-obesity medication reflected obesity prevalence across urban/rural areas
and deprivation. There was an unexplained two-fold difference, between the 25th and 75th percentile, in the GP practice
prescription of anti-obesity medication.
Conclusions: There is evidence of relative under-prescribing in males compared to females despite a similar prevalence
of obesity. While the prevalence (and presumably the health consequences) of obesity worsens with age, younger
females are more likely to be prescribed anti-obesity medication. This suggests an element of patient demand.
Educational material to improve the understanding of the role of anti-obesity medication, for patients and practitioners,
is recommended. But further study is needed to understand the factors responsible for the variation in prescribing
between GP practices.
Keywords: General practice, Anti-obesity agents, Socioeconomic factors, Weight loss, Obesity, Multi-level
modellingBackground
In the UK, it is estimated that up to 40% of the popula-
tion could be obese by 2030, based on recent trends [1].
This equates to an estimated £1.9 billion excess spend in
terms of healthcare costs [1]. The main interventions for
weight loss, behaviour and lifestyle changes, are difficult
to achieve and have modest long-term success rates [2].
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unless otherwise stated.appropriate intervention, such as bariatric surgery, in-
creases [3]. Whilst there would be huge economic benefits
if those eligible for surgery received it, [4] only a small
proportion of the population meet the current threshold
for this intervention (Body Mass Index ≥ 40 kg/m2).
In recent years, pharmacological treatment for obesity
has been increasing against a backdrop of decreasing
choice of available anti-obesity medications. Orlistat (brand
names Xenical/Alli) was first introduced in the UK and
Europe in 1998 and is currently the main treatment option
for those prescribed anti-obesity medication. In 1999, sibu-
tramine (brand name Reductil) was introduced as an anti-
obesity treatment option but was subsequently removed inral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ease [5]. In 2006, Rimonabant (brand name Acomplia)
was marketed as an anti-obesity drug but was removed
in November 2008 because of the risk of psychiatric side
effects [6].
In Northern Ireland, during 2009/2010 orlistat accounted
for approximately 80% of prescriptions for anti-obesity
medication increasing to 99% following the withdrawal of
sibutramine. In a meta-analysis of randomised control tri-
als (RCTs) orlistat in conjunction with a weight loss diet
reduced weight by 2.9 kg (95% CI 2.5 kg – 3.2 kg) and
slightly increased the proportion of patients achieving 5%
and 10% weight reduction thresholds [7]. It is not clear
what proportion of this reduction is due to the effects
of diet versus medication use but a reduction of this mag-
nitude, if achieved, is sufficient to significantly decrease
mortality and the risk of developing cardiovascular disease
or cancer [8]. Some studies have shown that anti-obesity
medications are a cost-effective form of treatment [9,10],
however, the research is often funded by pharmaceutical
companies and relies on large assumptions [11]. Despite
the potential benefits of using anti-obesity medication a
history of safety fears and a variety of side effects may have
hampered their use [5,12]. The latter has been observed in
RCTs of orlistat treatment where attrition rates of 30%
were observed across a range of RCTs [7].
Being overweight and obese is associated with increas-
ing age [13], gender (higher in males) [14], increasing
deprivation [15] and the built environment [16]. It is
therefore conceivable that the same factors may be asso-
ciated with the likelihood of being prescribed an anti-
obesity medication. Variations may also exist at a general
practice level reflecting the beliefs and practices of pri-
mary care physicians [17].
This study aims to: 1) relate uptake of anti-obesity
medications to need and; 2) quantify the amount of vari-
ation in prescribing of anti-obesity medication between
general practices.
Methods
This was a cross sectional analysis of anti-obesity medi-
cation prescribing in the Northern Ireland (NI) popula-
tion (~1.5 million people aged 16+ years). Data was
combined from two different sources to relate obesity
levels for different socio-demographic groups to the pre-
scription of anti-obesity medication among these groups.
Physical measurements of height and weight from the
NI Health and Wellbeing Survey (NI HWBS 2005/06)
were used to produce population estimates of obesity
(BMI ≥ 30 kg/m2) for the population aged 16 years and
over. The 2005/06 survey year was chosen as the most
contemporaneous data on objectively measured height
and weight for a representative sample of the NI popu-
lation. Data on all medications prescribed by GPs anddispensed by community pharmacists are collated cen-
trally in an enhanced prescription database (EPD) and in
2009 the population coverage was approximately 80% (the
shortfall being due to software incompatibility, but the
80% are known to be representative of the population in
terms of demography and geographical spread). Prescrib-
ing data were extracted for the period 1st April 2009 – 31st
March 2010, to reflect the most recent data available.
During 2009/10, approximately 85% of the population
had access to free prescriptions. For those that had to
cover the cost of their prescription, mainly those from
the most affluent groups, there was a minimal fee of
approximately £3 per prescription. Individuals were
excluded from the analysis if they had died, emigrated,
were institutionalised or were under 15 years of age dur-
ing the study period (n = 412,795). After exclusions, the
prescribing data related to a population of 1,492,982
individuals. The primary outcome was the prescription
of anti-obesity medication (British National Formulary
category 4.5 (orlistat, sibutramine and rimonabant)/ATC
codes A08AB01 (orlistat), A08AA10 (sibutramine), and
A08AX01 (rimonabant).
Predictors included age, classified into seven age groups
(Nine year age bands from 16-24, through to 75 and over)
and gender. An ecologically based indicator of socioe-
conomic status and of urban/rural residence was also in-
cluded. The former was based on the uptake of means
tested benefits and derived from the 2010 NI multiple
deprivation measure (NIMDM; www.nisra.gov.uk). It was
calculated at the Super Output Area with an average popu-
lation of ~2000 people. The distinction between urban and
rural dwelling individuals used the “settlement band” clas-
sification (www.nisra.gov.uk) which is based on population
size, population density and service provision. The settle-
ments were grouped as urban (band A, comprising the
largest city and hinterland), intermediate (bands B-G) or
rural dwelling (band H). General practice variables in-
cluded GP median age (grouped), gender ratio, practice
population size and the practice prevalence of obesity, from
the Quality and Outcomes Framework (QOF), categorised
into deciles (one = lowest; 10 = highest prevalence). The
study was approved by the Office for Research Ethics Com-
mittee (ORECNI; REC Reference number 10/NIR02/19).
Analytical strategy
The analysis was divided into two parts; the first utilised
multi-level logistic regression models to describe the
characteristics of patients who were prescribed anti-
obesity medication, adjusting for the clustering of pa-
tients within practices. Each of the factors described
were included in univariate analysis and factors signifi-
cantly associated with the likelihood of being prescribed
anti-obesity medication (P < 0.05) were included in the
final adjusted model (age group, settlement band and
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if there were significant differences according to gender.
The Variance Partition Coefficient (VPC) was calculated
using a linear threshold model [18]. The VPC describes
the importance of the general practice in explaining the
overall variation in the prescription of anti-obesity medica-
tion. The median Odds Ratio (mOR) was also calculated
to quantify the variation between clusters by comparing
two identical individuals from two randomly chosen dif-
ferent clusters [19]. The MOR can be directly compared
to the odds ratio for individual level variables [18].
The second part of the analysis related the distribution
of anti-obesity medication prescriptions to the estimated
number of obese individuals in the population derived
from the Health Survey to estimate the proportion of
obese individuals that received anti-obesity medication.
All analysis was carried out in STATA version 10 (STATA
Corp., College Station, TX, USA).
Results
Socio-demographic analysis of prescribing
During the study year an estimated 1.3% of the popu-
lation received anti-obesity medication; the prevalence
was higher among women (2.1%) than men (0.6%). The
gender difference in the prescription of anti-obesity
medication, which was higher in females, was evident at
all ages; prescribing in females peaked at younger ages
and to a greater extent than in men (Table 1). Approxi-
mately 3.0% of women aged 35–54 received anti-obesity
medication, compared to less than half that proportion
in men aged 45-64 years (the age of greatest prescrip-
tions for men). It is notable that amongst women the
prescription of anti-obesity medication was significantly
higher at younger (35–54 years) than at older ages, but the
reverse was true for men. For both males and females, the
proportion of the population prescribed anti-obesity medi-
cation fell significantly over the age of 65. A significant
interaction test in the logistic regression confirmed that
the prescription of anti-obesity medication by age varied
according to gender (LR χ2(6) = 437.7; P < 0.001), so all
subsequent analyses were stratified by gender.
The prescription of anti-obesity medication was sig-
nificantly higher in urban than in rural settings, although
in the fully adjusted models the gradients were more appar-
ent for men than for women. Compared to individuals in
urban areas, men in rural areas were 19.0% less likely to re-
ceive medication (95% CI for OR: 0.72, 0.91; P < 0.001) and
women in rural areas were 14.0% less likely to receive anti-
obesity medication (95% CI for OR: 0.79, 0.93; P = 0.001).
There was a steep and graded significant relationship
between the prescription of anti-obesity medication and
deprivation in females with a twofold higher likelihood
of receiving anti-obesity medication in the most deprived
compared to the least deprived areas (OR 1.95 95% CI:1.83, 2.07; P < 0.001 (fully adjusted model)). The relation-
ship with deprivation was less marked in males, with the
most deprived being 64.0% more likely to be prescribed
medication than those in the least deprived quintile (95%
CI for OR: 1.47, 1.82; P < 0.001).
Practice variation
The proportion of the general practice population that
was prescribed an anti-obesity medication ranged from
0% - 4.5% across the 358 practices, with an approximate
twofold difference between the 25th and 75th percentile.
The proportion of variation in prescribing that can be
attributed to the general practice was 7.2% for females
and 6.1% for males (VPC estimates). On the odds ratio
scale this translates to a median odds ratio of 1.61 in fe-
males and 1.55 in males. There was no association found
between the prevalence of obesity amongst the practice
population, the practice population size or the median
age/gender ratio of the GPs and the likelihood of being
prescribed anti-obesity medication.
Prescribing versus need
Table 2 shows how the estimated prevalence of obesity
from the Health and Wellbeing Survey varies across the
socio-demographic factors described above and relates
the prescription of anti-obesity medication to these esti-
mates. Overall, 24.4% of males and 23.5% of females
were estimated to be obese. However, fewer obese males
than obese females were prescribed anti-obesity medica-
tion (2.4% in males compared to 8.8% in females).
Comparing the prevalence of obesity to the number of
people prescribed anti-obesity medication we estimated
that one in 10 obese females in the 35–54 year age
groups received anti-obesity medication. In all other age
groups, the proportion receiving anti-obesity medication
was less than this, with 6.0% of obese 65–74 year olds
and 1.4% of those over 75 years receiving anti-obesity
medication. Compared to females, the estimated propor-
tion of obese males receiving anti-obesity medication
was lower across all age groups. Excluding the 16–24
and >75 years age groups where approximately 1.0% of
obese males were being treated, an estimated 2.0–3.0%
of obese males across all other age groups were pre-
scribed anti-obesity medication (range 1.6% – 3.5%).
Approximately one in 10 obese females in urban areas
received anti-obesity medication compared to 7.6% and
7.8% in intermediate and rural areas respectively. For
males the proportion of obese individuals receiving anti-
obesity medication is much lower; approximately 3.8% of
males in urban areas compared to 2.0% in the intermedi-
ate band and 1.9% in rural areas.
For both males and females, the socio-economic gradient
in estimated prescription of anti-obesity medication mat-
ched or exceeded that of obesity prevalence. In females, an
Table 1 The socio-demographic factors associated with the prescription of an anti-obesity medication and measures of




OR1 (95% CI) P-value Total population
(% on medication)
OR1 (95% CI) P-value
Age group
16-24 127 719 (0.9) 0.29 (0.27, 0.31) <0.001 133 610 (0.1) 0.15 (0.13, 0.18) <0.001
25-34 132 355 (2.2) 0.71 (0.68, 0.75) <0.001 135 349 (0.4) 0.49 (0.44, 0.55) <0.001
35-44 136 022 (3.0) 1.00 141 154 (0.7) 1.00
45-54 123 844 (2.9) 0.98 (0.93, 1.02) 0.35 127 073 (0.9) 1.29 (1.19, 1.40) <0.001
55-64 96 110 (2.6) 0.88 (0.84, 0.93) <0.001 96 422 (1.0) 1.42 (1.30, 1.55) <0.001
65-74 72 726 (1.5) 0.50 (0.46, 0.53) <0.001 65 679 (0.7) 0.98 (0.88, 1.09) 0.71
75+ 61 728 (0.3) 0.09 (0.08, 0.10) <0.001 39 721 (0.2) 0.22 (0.17, 0.28) <0.001
Settlement band
Urban 290 578 (2.5) 1.00 278 807 (0.7) 1.00
Intermediate 248 335 (2.0) 0.97 (0.89, 1.05) 0.43 239 862 (0.6) 0.90 (0.80, 1.01) 0.065
Rural 199 655 (1.6) 0.86 (0.79, 0.93) 0.001 208 669 (0.5) 0.81 (0.72, 0.91) <0.001
Area deprivation
Least deprived 154 850 (1.6) 1.00 149 806 (0.5) 1.00
2nd 162 180 (1.8) 1.22 (1.15, 1.30) <0.001 159 870 (0.6) 1.19 (1.08, 1.32) 0.001
3rd 131 458 (2.0) 1.45 (1.36, 1.54) <0.001 129 325 (0.5) 1.16 (1.04, 1.30) 0.009
4th 149 087 (2.2) 1.64 (1.55, 1.74) <0.001 146 440 (0.6) 1.28 (1.15, 1.42) <0.001
Most deprived 140 993 (2.9) 1.95 (1.83, 2.07) <0.001 141 897 (0.8) 1.64 (1.47, 1.82) <0.001
Measures of variation or clustering
Practice level variance (SE) 0.25 (0.024) 0.21 (0.026)
Variance Partition Coefficient (%) 7.2 6.1
Median Odds Ratio 1.61 1.55
1Odd Ratio (OR) and 95% Confidence Intervals from fully adjusted multi-level logistic regression models stratified by gender.
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medication in the most deprived areas compared to 8.1% in
the most affluent. For males the difference was smaller with
3.4% of obese individuals receiving ant-obesity medication
in the most deprived areas compared to 2.7% in the most
affluent.
Discussion
Main finding of this study
The data has shown that during this study period only a
small proportion of obese individuals are receiving anti-
obesity medication (approximately 5.8% overall). Whilst
the prevalence of obesity is similar in males and females,
females, and particularly those from younger age groups,
are more likely to be prescribed anti-obesity medication.
What is already known on this topic
Anti-obesity medication has been shown, in clinical tri-
als, to be an effective method of weight loss with a con-
sequential reduction in health risks [20]. The increasedprescription of anti-obesity medication has been re-
ported both in the UK [21], the US [22] and Canada
[12]. The US study, which used the Behavioural Risk
Factor Surveillance System across five states, was based
on self reported pill use and showed a higher use of
anti-obesity medication amongst females [22]. A UK
study, based on the prescription cost analysis system,
reported a 25-fold rise in orlistat prescriptions between
1998 and 2005 but presented no further information
about the individuals receiving the prescriptions or the
GP practices prescribing them [21].
What this study adds
Although it is known that the annual number of pre-
scriptions and cost of prescribed anti-obesity medication
has increased there is little information about how pre-
scription of these drugs relates to need and how much it
is influenced by the prescriber. To our knowledge, this
study is the first to explore both individual (patient) and
group (practice) level factors associated with the likelihood
Table 2 The proportion of obese individuals in the population and the estimated proportion of obese men and women















16-24 13.6 1162 6.7 12.0 152 0.9
25-34 23.7 2893 9.2 23.5 495 1.6
35-44 27.2 4070 11.0 28.5 1046 2.6
45-54 26.6 3641 11.1 31.9 1198 3.0
55-64 28.2 2511 9.3 29.3 982 3.5
65-74 25.6 1115 6.0 27.2 472 2.6
75+ 19.8 173 1.4 15.4 64 1.0
Settlement band
Urban 22.9 7111 10.7 18.8 1978 3.8
Intermediate 26.5 5009 7.6 28.9 1375 2.0
Rural 20.6 3222 7.8 25.6 994 1.9
Area deprivation
Least deprived 19.8 2488 8.1 19.3 778 2.7
2nd 21.3 2856 8.3 27.0 896 2.1
3rd 23.7 2605 8.4 27.7 670 1.9
4th 26.1 3302 8.5 24.7 864 2.4
Most deprived 28.4 4091 10.2 23.8 1139 3.4
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level statistical modelling. It also adds to the existing lit-
erature by including deprivation and urban/rural factors,
which are known to be associated with obesity.
The alignment of prescribing and prevalence data has
allowed us to estimate the equity of the prescription of
anti-obesity medication and while there are many as-
pects where prescribing appeared aligned with need,
there were examples where it is not. The most obvious
is the relative difference between the prescription of
anti-obesity medication amongst obese men and women.
The health survey data show that there were approxi-
mately equal proportions of obese men and women, but
at most ages it appeared that women were more than
three times as likely to receive anti-obesity medication
compared to men. This disparity is even more marked
considering the higher prevalence of diabetes in men [23]
and their greater risk of cardiovascular disease [24,25].
There are further disconnects between levels of obesity
and rates of prescribing across the age spectrum, especially
amongst women, with increased prescribing among obese
younger females compared to the older age groups. Again,
this is not in keeping with the gradients in risk as it is
older post-menopausal women who are likely to experi-
ence the greatest health gains from weight loss, as the risk
of other adverse outcomes, such as cardiovascular disease,increases [26]. Whether the gender and age differences ob-
served reflect a better perception of need and greater
health seeking behaviour amongst women or a lack of
awareness and reticence in seeking medical care amongst
men is not known [27]. Gender differences in the pre-
scription of anti-obesity medication may also reflect
the individual’s perception of their body weight and dis-
satisfaction with their body image. Females are more
likely to identify that they need to lose weight even if
they fall into the ‘normal’ category, using criteria de-
fined by the World Health Organisation [28]. Whilst
women experience body dissatisfaction throughout their
lifetime, the impact this has on self-esteem diminishes
with age [29] which may account for the fewer prescrip-
tions in the older age group.
The inverse care law, as proposed by Tudor Hart [30],
states that “the availability of good medical care tends to
vary inversely with the need for it in the population
served” [30]. This has been observed for a range of health
care services but was not evident in this study [31]. There
are two caveats: the first is that the ecologically assigned
socioeconomic status assumes that it is the deprived
people in the deprived areas who are getting the medica-
tion; and secondly, the observed gradient may still repre-
sent inequality [32] given the increased risk of negative
health outcomes in the more deprived populations [33,34].
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scribed anti-obesity medication is evident for both males
and females. For females, the residual heterogeneity be-
tween practices (mOR = 1.61) was comparable to living
in the 4th most deprived quintile (OR = 1.64) and was of
greater importance than age or settlement band for un-
derstanding the variation in the odds of being prescribed
anti-obesity medication. In males, the residual hetero-
geneity between practices (mOR = 1.55) was comparable
to the most deprived quintile (OR = 1.64) and was of
greater importance than age or settlement band for un-
derstanding the variation in the odds of being prescribed
anti-obesity medication. The variation in the prescrip-
tion of anti-obesity medication at the general practice
level may be related to reluctance by some General Prac-
titioners (GPs) to prescribe anti-obesity medication if
they believe obesity is better treated through lifestyle
changes [35]. Indeed, using anti-obesity medication is
cited as the least likely treatment approach by physicians
[35]. It is also possible that both individuals and GPs avoid
the use of pharmacotherapy because of a disconnect in
their beliefs about the causes and solutions of obesity
[36,37], an uncertainty about appropriateness and safety,
concern about side effects particularly for orlistat [36], or
because of the availability of alternative management op-
tions, for example, access to dieticians.
Strengths and limitations
This study had two main strengths: 1) the ability to ac-
cess individual level data for the prescription of anti-
obesity medication across the population and; 2) the use
of multi-level modelling to account for individual and
GP practice factors associated with the prescription of
anti-obesity medication. A limitation to this analysis was
the disconnect in the time periods used to describe
obesity prevalence (2005/06) and the prescribing of anti-
obesity medication (2009/10). Whilst the time periods
do not overlap it is unlikely that the patterning of obes-
ity prevalence will have changed over this time. It is pos-
sible that the overall prevalence of obesity may have
changed; the direction for this is likely to have been a
slight increase and therefore estimates relating need to
observed prescribing are conservative. Furthermore, as
this study was observational in nature it was not possible
to infer causality. An assumption was made that pre-
scribing should reflect the National Institute for Health
and Clinical Excellence (NICE) guidelines. However, we
cannot infer the clinical basis for the prescription; that
the individuals were obese or were overweight with
co-morbid conditions with unsuccessful weight loss after
at least three months of managed care. We also cannot
confirm that the medication was actually taken nor could
we account for patient or practitioners beliefs and know-
ledge of obesity, in general, or of anti-obesity medication. Itis possible, therefore, that variations in prescribing may be
due to clinical contraindications or to patient/practitioner
preference but the size of the differences observed would
make this unlikely. It would have been helpful to have
individual-level data relating to BMI as well as other per-
sonal attributes such as socio-economic status. These data
were not readily available.
Our study lacked a measure of other risk factors
which presumably would be higher in males; therefore
the male to female ratio of “need versus demand” is
likely to be more marked than reported here. The ana-
lysis is based on the prescription of anti-obesity medi-
cation from GPs, where the majority of prescribing for
anti-obesity medication occurs. This excludes drugs dis-
pensed in hospitals, private prescriptions or those supplied
over-the-counter by community pharmacies. The latter
may be the treatment of choice for those in more affluent
populations.
Conclusions
Overall, the pattern of prescribing for anti-obesity medi-
cation appears to reflect the needs of the population.
However, there is some evidence of socially determined
prescribing, specifically reflected in under-prescribing
amongst males and higher prescribing amongst younger
females. Further studies linking an individual’s BMI and
co-morbidity to the prescription of anti-obesity medica-
tion may help to elucidate if individual level need is be-
ing met. Educational material to inform the proper use
of anti-obesity medication, amongst patients and practi-
tioners, and to help with realistic goal setting should be
encouraged. There is also a need to understand the fac-
tors responsible for the variation in prescribing between
practices.
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